TQB-3728

Phase Ib dose escalation phase: Primary purpose To evaluate the safety and tolerability of TQB3728 tablets in patients with non-surgical treatment of locally advanced head and neck tumors undergoing concurrent chemoradiotherapy, and to determine the Phase II recommended dose (RP2D) Secondary purpose To evaluate the preliminary efficacy of TQB3728 tablets in patients with non-surgical treatment of locally advanced head and neck tumors undergoing concurrent chemoradiotherapy, as well as the pharmacokinetic (PK) characteristics of oral administration Phase II dose expansion phase: Primary purpose To evaluate the preliminary efficacy of TQB3728 tablets in patients with non-surgical treatment of locally advanced head and neck squamous cell carcinoma (SCCHN) undergoing concurrent chemoradiotherapy Secondary purpose To evaluate the safety of TQB3728 tablets in patients with non-surgical treatment of locally advanced head and neck squamous cell carcinoma (SCCHN) undergoing concurrent chemoradiotherapy Exploratory purpose To explore the preliminary efficacy and safety of TQB3728 tablets in patients with non-surgical treatment of locally advanced head and neck adenocarcinoma undergoing concurrent chemoradiotherapy